PSUR vs DSUR vs PBRER: Key Differences Explained

PSUR, PBRER and DSUR are periodic safety reports for different stages of a drug's life. A PBRER assesses benefit-risk for a marketed product over a set interval, and a PSUR is the older name for a similar report. A DSUR is an annual report on an investigational drug during development.
If you are comparing psur vs dsur vs pbrer, the first question is the product's stage: marketed or in development. The three reports share content, and ICH designed common sections so they can be reused across them [1]. This article compares their scope, deadlines and DSUR structure, and walks through a timing example.
What is the difference between a PSUR, PBRER and DSUR?
The PBRER is the ICH E2C(R2) report for marketed products, and its scope is wider than the earlier PSUR format [1]. It asks for a cumulative benefit-risk evaluation, not only a summary of adverse events. Some regions still use the PSUR name, so the local requirement decides which template you follow.
Build These Skills Now
Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.
A DSUR is the ICH E2F report for an investigational drug. It is an annual report to regulatory authorities, and it must be comprehensive and stand alone, because the DSUR and PSUR focus on different subject matter and have different periodicities and recipients [2]. Safety data from trials of marketed drugs can appear in both, so expect some repetition [2].
In the US, 21 CFR 314.80 sets the periodic adverse drug experience reporting rules for approved applications [3]. Each periodic report must include a narrative summary and analysis of the information in the report, plus an analysis of the 15-day Alert reports submitted in that interval [3]. This is a regulatory framework in its own right, so do not assume the ICH layouts map onto it one for one.
| Feature | PSUR | PBRER | DSUR |
|---|---|---|---|
| Product stage | Marketed product (older term) | Marketed product | Investigational drug in development |
| Governing guidance | Earlier periodic format; local rules apply | ICH E2C(R2) [1] | ICH E2F [2] |
| Core question | Cumulative safety of the marketed product | Cumulative benefit-risk of the marketed product | Cumulative safety of the investigational drug and development status |
| Reporting interval | Set by the regulator | Usually 6-month or 12-month data intervals, or longer if agreed [1] | Annual, with a stated reporting period [2] |
| Main recipient | Regulatory authorities | Regulatory authorities | Regulatory authorities; the executive summary may suit ethics committees [2] |
| Shared content | Overlaps with DSUR and PBRER | Appendix D lists sections shareable with a DSUR or safety specification [1] | Marketing experience may overlap with the PSUR [2] |
When is each periodic report due?
Timing depends on the report type, the data lock point (DLP) and the regional rule. For a PBRER, the DLP is the cut-off for the data included, and the submission clock starts from it [1]. The DSUR is annual, and its reporting period is stated on the title page [2].
Use these steps to calculate a PBRER deadline:
- Confirm the DLP and treat that date as day 0.
- Identify the interval: 6-month or 12-month PBRERs are due within 70 calendar days; intervals over 12 months within 90 calendar days [1].
- For an ad hoc PBRER requested by a regulator, the default is 90 calendar days unless the request states otherwise [1].
- If a national or regional requirement differs, agree the timeline with that authority [1].
Worked example. A 6-month PBRER has a DLP of 31 December in a non-leap year. Day 0 is 31 December, so day 31 is 31 January, day 59 is 28 February and day 70 is 11 March. The submission deadline is 11 March [1].
US periodic reports follow a different clock. Under 21 CFR 314.80, quarterly reports are due within 30 days of the close of each quarter for 3 years from approval, and annual reports within 60 days of the approval anniversary [3]. FDA can extend these requirements or change the timing on written notice [3].
| Report | Clock starts at | Standard deadline | Source |
|---|---|---|---|
| PBRER, 6 or 12-month interval | Data lock point | 70 calendar days | [1] |
| PBRER, interval over 12 months | Data lock point | 90 calendar days | [1] |
| Ad hoc PBRER | Regulator request | 90 calendar days unless specified | [1] |
| US quarterly periodic report | Close of quarter | 30 days after quarter close, first 3 years | [3] |
| US annual periodic report | Approval anniversary | 60 days after anniversary | [3] |
| DSUR | Annual reporting period | Annual; confirm the date with the relevant authority | [2] |
What sections does a DSUR contain?
The ICH E2F recommended format includes a title page, an executive summary, a table of contents and 20 numbered sections, with appendices [2]. Every section should be completed, and where no information exists the report should say so [2]. Knowing the grouping helps when you learn what is a DSUR in practice.
- Status and actions: 1 Introduction, 2 Worldwide Marketing Approval Status, 3 Actions Taken for Safety Reasons, 4 Changes to Reference Safety Information [2].
- Exposure and trial data: 5 Inventory of Clinical Trials, 6 Estimated Cumulative Exposure, 7 Data in Line Listings and Summary Tabulations, 8 Significant Findings from Clinical Trials [2].
- Other sources: 9 Non-interventional Studies, 10 Other Clinical Trial Safety Information, 11 Safety Findings from Marketing Experience, 12 Non-clinical Data, 13 Literature, 14 Other DSURs, 15 Lack of Efficacy, 16 Region-Specific Information, 17 Late-Breaking Information [2].
- Assessment and conclusions: 18 Overall Safety Assessment (18.1 Evaluation of the Risks; 18.2 Benefit-risk Considerations), 19 Summary of Important Risks, 20 Conclusions [2].
A simple check before submission: confirm that every section is either completed or marked as not applicable, that the executive summary reflects Sections 18 and 19, and that the title page lists the DSUR number, reporting period and date [2].
Key takeaways
- PBRER (ICH E2C(R2)) covers marketed products and evaluates benefit-risk; PSUR is the older name for a similar marketed-product report [1].
- DSUR (ICH E2F) is an annual report on an investigational drug and has 20 numbered sections [2].
- PBRER deadlines run from the data lock point: 70 days for 6- and 12-month intervals, 90 days for longer intervals [1].
- US periodic reports under 21 CFR 314.80 follow a quarterly-then-annual schedule that is separate from ICH timelines [3].
- Shared sections across the reports are intended to reduce duplication, but each report must stand alone [1][2].
Build These Skills Now
Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.
How do you practise PSUR, DSUR and PBRER writing?
Reading templates builds recognition, but writing builds skill. Practise by mapping one sample dataset to the DSUR sections and then to the PBRER headings, and note where content can be reused. The PSUR & DSUR Reporting Certification at ZANE ProEd covers ICH E2C(R2) and E2F structure, cumulative data compilation and quality review, and you can find it at the PSUR & DSUR Reporting Certification course page.
Frequently asked questions
Can the same data serve a PBRER and a DSUR?
Partly. ICH E2C(R2) allows sections to be shared through a modular approach, and Appendix D lists which PBRER sections can be used for a DSUR [1]. Each report must still be comprehensive on its own [2].
Does a DSUR replace a marketed-product report?
No. The guidance treats the DSUR and the PSUR or PBRER as separate reports with different subject matter, periodicities and recipients, so one does not stand in for the other [2].
What is an ad hoc PBRER?
An ad hoc PBRER is a report outside the routine schedule, which some regulators may request [1]. Unless the request says otherwise, it is due within 90 calendar days [1].
Which US rule covers periodic reports?
21 CFR 314.80 covers postmarketing reporting of adverse drug experiences, including quarterly reports for 3 years after approval and annual reports after that [3].
Sources
- ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER) (R2). ICH.
- ICH E2F: Development Safety Update Report (DSUR) (Step 4 (2010)). ICH.
- 21 CFR 314.80: Postmarketing reporting of adverse drug experiences (eCFR (current)). FDA.
Build These Skills Now
Programs from ZANE ProEd Academy that directly address the skill gaps discussed above.
Follow Zane ProEd on Google
Preferred SourceAdd our publication as a preferred source to get the latest clinical research guides, industry updates, and career intel directly in your Google Top Stories & AI Overviews.